Dry Age Macular Degeneration (AMD) Pipeline Assessment, 2022 | Insights into the Current and Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies

 Breaking News
  • No posts were found

Dry Age Macular Degeneration (AMD) Pipeline Assessment, 2022 | Insights into the Current and Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies

November 22
19:34 2022
Dry Age Macular Degeneration (AMD) Pipeline Assessment, 2022 | Insights into the Current and Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, several prominent pharma and biotech giants are actively working in the Dry Age Macular Degeneration (AMD) therapeutics landscape. Companies are developing new therapies based on different Routes of Administration (RoA), Mechanisms of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Dry Age Macular Degeneration Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Dry Age Macular Degeneration Market. 

The Dry Age Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Dry Age Macular Degeneration (AMD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Dry Age Macular Degeneration and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age Macular Degeneration Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dry Age Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Dry Age Macular Degeneration Therapeutic Segment:


Dry Age Macular Degeneration (AMD)Therapeutics Landscape

A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust FDA-approved therapies. In contrast, there are not any approved treatments for dry AMD. The management of dry AMD consists of observation, regular follow-up evaluations, and documentation for timely recognition of visual function deterioration with appropriate rehabilitation and early CNV detection. To improve the treatment scenario, globally, several key companies are actively working in the Dry Age Macular Degeneration Therapeutics landscape.

The Leading Companies in the Dry Age Macular Degeneration (AMD) Market Include:

  • Gemini Therapeutics

  • Allegro Ophthalmics

  • Gyroscope Therapeutics

  • Alkeus Pharmaceuticals

  • IVERIC bio

  • Luxa Biotechnology

  • Regenerative Patch Technologies

  • OliX Pharmaceuticals

  • Eyestem

And Many Others

Dry Age Macular Degeneration (AMD) Therapies Covered in the Report Include:

  • Eyecyte RPE

  • OLX301A



  • Zimura

  • ALK-001

  • GT005

  • Risuteganib

  • GEM103

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Dry Age Macular Degeneration Current Treatment Patterns

4. Dry Age Macular Degeneration – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Dry Age Macular Degeneration Late Stage Products (Phase-III)

7. Dry Age Macular Degeneration Mid-Stage Products (Phase-II)

8. Dry Age Macular Degeneration Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dry Age Macular Degeneration Discontinued Products

13. Dry Age Macular Degeneration Product Profiles

14. Key Companies in the Dry Age Macular Degeneration Market

15. Key Products in the Dry Age Macular Degeneration Therapeutics Segment

16. Dormant and Discontinued Products

17. Dry Age Macular Degeneration Unmet Needs

18. Dry Age Macular Degeneration Future Perspectives

19. Dry Age Macular Degeneration Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Other Trending Healthcare Reports By DelveInsight

Dry Age Macular Degeneration (AMD) Market Insight

“Dry Age Macular Degeneration Market Outlook 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dry Age Macular Degeneration market size, shares, and trends analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles